194 related articles for article (PubMed ID: 31973075)
1. Impact of Truncated
Moreira IB; Pinto F; Gomes C; Campos D; Reis CA
Cells; 2020 Jan; 9(2):. PubMed ID: 31973075
[TBL] [Abstract][Full Text] [Related]
2. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori-Infected CAPZA1-Overexpressing Cells.
Tsugawa H; Kato C; Mori H; Matsuzaki J; Kameyama K; Saya H; Hatakeyama M; Suematsu M; Suzuki H
Cell Mol Gastroenterol Hepatol; 2019; 8(3):319-334. PubMed ID: 31146068
[TBL] [Abstract][Full Text] [Related]
3. O-glycan truncation enhances cancer-related functions of CD44 in gastric cancer.
Mereiter S; Martins ÁM; Gomes C; Balmaña M; Macedo JA; Polom K; Roviello F; Magalhães A; Reis CA
FEBS Lett; 2019 Jul; 593(13):1675-1689. PubMed ID: 31077346
[TBL] [Abstract][Full Text] [Related]
4. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.
Freitas D; Campos D; Gomes J; Pinto F; Macedo JA; Matos R; Mereiter S; Pinto MT; Polónia A; Gartner F; Magalhães A; Reis CA
EBioMedicine; 2019 Feb; 40():349-362. PubMed ID: 30662000
[TBL] [Abstract][Full Text] [Related]
5. CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium.
Bertaux-Skeirik N; Wunderlich M; Teal E; Chakrabarti J; Biesiada J; Mahe M; Sundaram N; Gabre J; Hawkins J; Jian G; Engevik AC; Yang L; Wang J; Goldenring JR; Qualls JE; Medvedovic M; Helmrath MA; Diwan T; Mulloy JC; Zavros Y
J Pathol; 2017 Aug; 242(4):463-475. PubMed ID: 28497484
[TBL] [Abstract][Full Text] [Related]
6. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells.
Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S
Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417
[TBL] [Abstract][Full Text] [Related]
7. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Mashima T; Iwasaki R; Kawata N; Kawakami R; Kumagai K; Migita T; Sano T; Yamaguchi K; Seimiya H
Br J Cancer; 2019 Nov; 121(10):846-856. PubMed ID: 31607750
[TBL] [Abstract][Full Text] [Related]
8. CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer.
Choi ES; Kim H; Kim HP; Choi Y; Goh SH
Sci Rep; 2017 Jul; 7(1):4930. PubMed ID: 28694503
[TBL] [Abstract][Full Text] [Related]
9. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
[No Abstract] [Full Text] [Related]
10. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression.
Yasui W; Kudo Y; Naka K; Fujimoto J; Ue T; Yokozaki H; Tahara E
Int J Oncol; 1998 Jun; 12(6):1253-8. PubMed ID: 9592182
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
12. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer.
Go SI; Ko GH; Lee WS; Kim RB; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2016 Jan; 48(1):142-52. PubMed ID: 25779358
[TBL] [Abstract][Full Text] [Related]
13. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.
Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa.
Ishimoto T; Izumi D; Watanabe M; Yoshida N; Hidaka K; Miyake K; Sugihara H; Sawayama H; Imamura Y; Iwatsuki M; Iwagami S; Baba Y; Horlad H; Komohara Y; Takeya M; Baba H
J Gastroenterol; 2015 Jul; 50(7):751-7. PubMed ID: 25479940
[TBL] [Abstract][Full Text] [Related]
15. CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.
Taniguchi D; Saeki H; Nakashima Y; Kudou K; Nakanishi R; Kubo N; Ando K; Oki E; Oda Y; Maehara Y
Cancer Med; 2018 Dec; 7(12):6258-6268. PubMed ID: 30474922
[TBL] [Abstract][Full Text] [Related]
16. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.
Ghatak S; Hascall VC; Markwald RR; Misra S
J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation.
Suwannakul N; Ma N; Thanan R; Pinlaor S; Ungarreevittaya P; Midorikawa K; Hiraku Y; Oikawa S; Kawanishi S; Murata M
Mediators Inflamm; 2018; 2018():4867234. PubMed ID: 30402042
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation.
Jogo T; Oki E; Nakanishi R; Ando K; Nakashima Y; Kimura Y; Saeki H; Oda Y; Maehara Y; Mori M
Gastric Cancer; 2021 Sep; 24(5):1089-1099. PubMed ID: 33963958
[TBL] [Abstract][Full Text] [Related]
20. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence.
Hirata K; Suzuki H; Imaeda H; Matsuzaki J; Tsugawa H; Nagano O; Asakura K; Saya H; Hibi T
Br J Cancer; 2013 Jul; 109(2):379-86. PubMed ID: 23778530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
